Telletamine detection card as well as preparation method and application thereof

Abstract

The invention relates to the technical field of biological detection, in particular to a teletamine detection card as well as a preparation method and application thereof. The invention provides a tiletamine detection card. The tiletamine detection card comprises a bottom plate, a sample loading pad, a colloidal gold pad, an NC (nitrocellulose) membrane and a water absorption pad, a sample loading pad, a colloidal gold pad, an NC (nitrocellulose) membrane and a water absorption pad are sequentially arranged on the bottom plate along the liquid chromatography direction; the colloidal gold pad is coated with a colloidal gold labeled teletamine monoclonal antibody and a colloidal gold labeled first antibody; a detection line and a quality control line are sequentially arranged on the NC membrane along the liquid chromatography direction; the detection line is coated with a teletamine conjugate; the quality control line is coated with a second antibody; the second antibody can be specifically combined with the first antibody. The teletamine detection card and the colloidal gold detection kit provided by the invention have the advantages of good application effect, good specificity and good repeatability.

Description

Technical Field

[0001] This invention relates to the field of biological detection technology, specifically to a telexamine detection card, its preparation method, and its application. Background Technology

[0002] Tiletamine is a veterinary anesthetic, and its abuse can lead to serious health risks. Tiletamine is a white or pale yellow powder, a dissociative anesthetic, and is clinically used for induction of anesthesia or in combination with other anesthetics to enhance the anesthetic effect. Small amounts can produce hallucinogenic effects, leading to symptoms such as decreased body temperature, tachycardia, permanent neurological damage, persistent slowed movement, vomiting, and howling; overdose can cause general anesthesia, confusion, and even death.

[0003] Drug testing kits are rapid detection tools developed based on colloidal gold immunochromatography technology. They are mainly used to screen for drug components in human urine or hair. The principle is to achieve qualitative detection through the competitive inhibition reaction between colloidal gold-labeled antibodies and drug antigens, and the results can be interpreted through color bands. Therefore, there is an urgent need to research telactamine testing kits. Summary of the Invention

[0004] Therefore, the technical problem to be solved by the present invention is to overcome the defect of telexamine being difficult to detect in the prior art, thereby providing a telexamine detection card and a telexamine colloidal gold detection kit, which are convenient to detect, fast to detect, and highly efficient to detect.

[0005] Therefore, the present invention provides the following technical solution: This invention provides a telexamine detection card, comprising a base plate, a sample loading pad, a colloidal gold pad, an NC membrane, and an absorbent pad; the base plate is provided with the sample loading pad, colloidal gold pad, NC membrane, and absorbent pad sequentially along the liquid chromatography direction; The colloidal gold pad is coated with a colloidal gold-labeled teletamine monoclonal antibody and a colloidal gold-labeled first antibody; the NC membrane is provided with a detection line and a control line in sequence along the liquid chromatography direction; the detection line is coated with a teletamine conjugate; the control line is coated with a second antibody; the second antibody can specifically bind to the first antibody.

[0006] Optionally, the first antibody includes a rabbit IgG antibody; the second antibody includes a goat anti-rabbit polyclonal antibody; and the teretamine conjugate includes a teretamine-bovine serum albumin conjugate.

[0007] Optionally, the concentration of the colloidal gold-labeled telexamine monoclonal antibody on the colloidal gold pad is 2–4 μg / mL; The concentration of the first antibody labeled with colloidal gold on the colloidal gold pad is 10-20 μg / mL; The coating concentration of the teretamine conjugate on the detection line is 0.3–0.6 mg / mL; The coating concentration of the second antibody on the quality control line is 1.0–2.0 mg / mL.

[0008] In a specific embodiment, the teletamin monoclonal antibody was purchased from Fuzhou Chuangdian Biotechnology Co., Ltd., and the teletamin-bovine serum albumin conjugate was purchased from Fuzhou Chuangdian Biotechnology Co., Ltd.

[0009] Optionally, the base plate includes a plastic substrate.

[0010] Optionally, the plastic substrate is provided with a sample pad and an absorbent pad, both of which are provided with a protective film. An NC film (nitrocellulose film) is provided below the sample pad and the absorbent pad. The two ends of the NC film overlap with the sample pad and the absorbent pad respectively, and the overlapping parts of the two ends of the NC film are located below the sample pad and the absorbent pad respectively. The connection between the sample pad and the NC membrane is provided with a colloidal gold pad (solid-phase colloidal gold). One end of the colloidal gold pad overlaps with the NC membrane and is located below the sample pad. The NC membrane is sequentially coated with a detection line and a control line. The detection line on the NC membrane is coated with a conjugate of telactamine and bovine serum albumin, and the control line on the NC membrane is coated with goat anti-rabbit polyclonal antibody. The colloidal gold pad is coated with telactamine monoclonal antibody and rabbit IgG antibody.

[0011] Optionally, the colloidal gold pad, NC membrane, and absorbent pad need to overlap by 1-2 mm.

[0012] Optionally, the NC membrane is sealed after coating using a sealing treatment soaking solution prepared with phosphate buffer; optionally, the concentration of the phosphate buffer is 0.01M.

[0013] Preferably, the substrate of the NC membrane comprises a nitrocellulose membrane; the substrate of the colloidal gold pad comprises polyester fiber strips.

[0014] Preferably, on the NC membrane, the detection line is located on the side closer to the sample application end, and the quality control line is located on the side farther from the sample application end.

[0015] This invention provides a method for preparing the telexamine test card described in the above technical solution, comprising: 1) Spray the colloidal gold-labeled telactamine monoclonal antibody solution and the first antibody solution onto the pretreated colloidal gold pad to obtain a colloidal gold pad coated with telactamine monoclonal antibody and the first antibody. 2) Spray teletamine conjugate onto the detection line of the NC membrane and spray the second antibody onto the control line of the NC membrane to obtain the coated NC membrane; the NC membrane is then blocked using a blocking treatment soaking solution prepared with phosphate buffer. The sample pad, the colloidal gold pad prepared in step 1), the NC membrane prepared in step 2), and the absorbent pad are sequentially pasted onto the base plate to obtain the telactamine detection card.

[0016] The present invention provides a terleptamine colloidal gold detection kit, the kit comprising the above-described terleptamine detection card or the terleptamine detection card prepared by the above-described preparation method.

[0017] Optionally, the kit also includes a housing for loading a telexamine test card.

[0018] This invention provides a method for detecting telexamine, which is not for the purpose of disease diagnosis and treatment. The method uses the telexamine test card described above or the telexamine test card prepared by the above preparation method or the telexamine colloidal gold test kit described above to detect the sample to be tested.

[0019] Preferably, the sample to be tested includes urine.

[0020] The telexamine detection card and telexamine colloidal gold detection kit of this invention employ highly specific antibody-antigen reaction and immunochromatographic technology to rapidly and qualitatively detect telexamine in human urine using a competitive inhibition method. During testing, urine sample is dropped into the reagent card well, and the sample is then chromatographically purified upwards along the liquid chromatography direction due to capillary action. If the concentration of telexamine in the urine sample is below 1000 ng / mL, the colloidal gold-labeled telexamine monoclonal antibody on the colloidal gold pad cannot bind completely to the telexamine in the urine. Therefore, the colloidal gold-labeled telexamine monoclonal antibody will bind to the telexamine conjugate immobilized on the NC membrane during chromatography, resulting in a purple-red band within the detection line of the NC membrane. If the concentration of telexamine in the urine sample is higher than 1000 ng / mL, the colloidal gold-labeled telexamine monoclonal antibody on the colloidal gold pad will bind completely to the telexamine in the urine. Therefore, it will not bind to the telexamine conjugate within the detection line of the NC membrane, and no purple-red band will appear. Negative urine samples will show a purple-red band within the detection line (T) of the NC membrane due to the lack of antibody-antigen competition during the testing process.

[0021] Regardless of the presence of teretamine in the urine sample, the first antibody coated with colloidal gold on the colloidal gold pad and the second antibody coated on the control line specifically bind to each other, and a purple-red band will appear within the control line (C) of the NC membrane.

[0022] Result interpretation criteria: Negative samples (i.e., no teretamine detected in the sample): Two purple-red bands appear at the test line and the control line in the observation window. Positive samples (i.e., the sample contains teretamine): Only one purple-red band appears at the control line in the observation window.

[0023] This invention provides the application of the terlethamine detection card described in the above-described technical solution, or the terlethamine detection card prepared by the preparation method described in the above-described technical solution, or the terlethamine colloidal gold detection kit described in the above-described technical solution, in the detection of terlethamine.

[0024] The technical solution of this invention has the following advantages: 1. The telexamine test card provided by this invention is convenient, fast, and efficient.

[0025] 2. The telexamine colloidal gold detection kit provided by this invention is convenient, fast, and efficient.

[0026] The teletamine test strip and test kit are not limited by time or location, are easy to use, provide rapid testing, can be completed in one step, and have no contamination.

[0027] The telexamine detection card and kit of the present invention utilize the principles of competitive inhibition and immunochromatography for in vitro qualitative detection of telexamine content in human urine. It is used for initial screening, exhibiting good repeatability and specificity, small batch-to-batch variation, and accurate and reliable test results.

[0028] In the preparation method of the telexamine test card provided by the present invention, the colloidal gold pad and NC membrane in the telexamine test card are sealed with phosphate buffer solution, which can reduce contamination. Attached Figure Description

[0029] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0030] Figure 1 This is a structural diagram of a telexamine test card according to an embodiment of the present invention, wherein 1 corresponds to a plastic substrate, 2 corresponds to a sample loading pad, 3 corresponds to an absorbent pad, 4 corresponds to a protective film, 5 corresponds to a nitrocellulose membrane (NC membrane), and 6 corresponds to a colloidal gold adsorption pad. Figure 2 This is a structural diagram of a telexamine detection card according to an embodiment of the present invention, wherein area A, the entry area, corresponds to the sample pad, area B, the absorption pad, and area E, the nitrocellulose membrane, corresponds to the NC membrane. Figure 3 The images show the top and bottom covers of the Tiltamine Colloidal Gold Assay Kit, with the top part showing the top cover and the bottom part showing the bottom cover. Figure 4 This is a complete diagram of the Tileta Colloidal Gold Assay Kit. Detailed Implementation

[0031] The following embodiments are provided to better understand the present invention and are not limited to the preferred embodiments described. They do not constitute a limitation on the content and scope of protection of the present invention. Any product that is the same as or similar to the present invention, derived by any person under the guidance of the present invention or by combining the features of the present invention with other prior art, falls within the protection scope of the present invention.

[0032] For experiments not specifically described in the examples, the procedures or conditions should be followed according to the conventional experimental procedures described in the literature in this field. Reagents or instruments whose manufacturers are not specified are all commercially available conventional reagent products.

[0033] Example 1: Preparation of Telexamine Detection Card 1. Preparation of NC membrane - nitrocellulose membrane: (1) Select a nitrocellulose membrane with an 8μm pore size and cut the membrane into specifications with a width of ≥2.0cm and a length of 30.5cm as needed; (2) Prepare a teletamine and bovine serum albumin conjugate solution with 0.01M phosphate buffer and the concentration of the conjugate coated on the detection line is 0.5 mg / mL; prepare a goat anti-rabbit polyclonal antibody solution with 0.01M phosphate buffer and the quality control line is coated with 1.5 mg / mL goat anti-rabbit polyclonal antibody.

[0034] (3) Determine and mark the antibody-coated surface of the nitrocellulose membrane. Spray the solution of telostatin conjugate with bovine serum albumin and the solution of goat anti-rabbit polyclonal antibody to be coated evenly on the nitrocellulose membrane in parallel. The distance between the detection line and the control line is controlled at 0.5 cm. The nitrocellulose membrane is dried at a constant temperature of 2℃ to 30℃ for later use. (4) Prepare the sealing treatment soaking solution. Add the actual production amount of purified water to the mixing tank. Measure the final concentration of phosphate buffer (pH 7.4) using a graduated cylinder. Weigh the sugar sucrose, blocking protein bovine serum albumin, and preservative Proclin 300 using an electronic analytical balance. Add them directly to the mixing tank and stir until completely dissolved. Add purified water to make up to the required volume. Stir thoroughly for at least 30 minutes to obtain the sealing treatment soaking solution. In the immersion solution for the sealing treatment, the mass percentage concentration (w / v, g / 100mL) of sugar was 0.5%, the mass percentage concentration of blocking protein was 1%, and the mass percentage concentration of preservative was 0.05%. (5) Place the coated nitrocellulose membrane in the treatment tank, add the prepared sealing treatment soaking solution (4) above, and ensure that each membrane is completely immersed in the sealing treatment soaking solution (4) above for 30 minutes, and ensure that the membrane does not move or overlap. After 30 minutes, take the membrane out of the treatment tank and pour out the sealing treatment soaking solution (4) above. Take the membrane out of the treatment tank, use tweezers to pull the membrane of each frame back to ensure that the membrane does not move outside the frame and that there is no membrane re-attachment. Then use tweezers to pull the membrane on the gauze to dry slightly. (6) Drying the film: Peel off the white paper in the middle of the cut line on the double-sided tape of the plastic substrate. Use tweezers to place the film precisely in the blank position in the center of the plastic substrate, with the cut corner at the upper right. The right side of the plastic substrate should be flush with the right side of the film to avoid errors during the production process and ensure that the color development position is relatively accurate. When applying the film, apply it all to the end of the C line. After the film is applied to the plastic substrate, smooth the film surface through the double-sided tape to avoid air bubbles. Control the indoor temperature at 18-28℃ and the relative humidity at ≤40%, and ensure that the air in the drying room can circulate and that the dehumidifier air does not blow directly onto the film surface. The drying time should not be less than 4 hours, and then it can be used for later use.

[0035] 2. Marking and solid phase of polyester fiber strips in colloidal gold pads: The colloidal gold pad uses polyester fiber strips as the base material.

[0036] (1) Preparation of colloidal gold complex solution: Add the actual production amount of purified water to the mixing tank, weigh trehalose, bovine serum albumin, trisodium citrate, polyethylene glycol and preservative Proclin 300 using an electronic analytical balance, add the above raw materials directly to the mixing tank and stir until completely dissolved, add purified water to make up to the required volume, stir thoroughly and evenly for more than 30 minutes to obtain colloidal gold complex solution for later use; in the colloidal gold complex solution, the mass percentage of trehalose is 5%, the mass percentage of bovine serum albumin is 2%, the mass percentage of trisodium citrate is 0.5%, the mass percentage of polyethylene glycol is 0.05%, and the mass percentage of preservative Proclin 300 is 0.05%.

[0037] (2) Preparation of colloidal gold solution: 792 mL of purified water was measured with a graduated cylinder, and 8 mL of 2% (g / 100 mL) chloroauric acid solution was added. After mixing and boiling, 15 mL of 1% (g / 100 mL) trisodium citrate solution was added. After boiling for 10 min, the solution was cooled and diluted to 800 mL for later use to obtain colloidal gold solution 1.

[0038] (3) Measure the required amount of colloidal gold solution 1 with a graduated cylinder, adjust the pH to 6.5-7.0, that is, add 0.2 mol / L potassium carbonate solution with a volume percentage concentration of 0.50%, stir on a magnetic stirrer for 15 min, and obtain colloidal gold solution 2.

[0039] Take the levothamine monoclonal antibody, dilute it with double-distilled water, and label it at 3 μg / ml in colloidal gold solution 2. The volume ratio of double-distilled water to colloidal gold solution 2 is 1:100. Mix thoroughly and stir on a magnetic stirrer for 30 min. Then add 0.5‰ (v / v) of stabilizer PEG and stir for another 30 min. Centrifuge, collect the precipitate, and reconstitute it with colloidal gold reconstitution solution at 2% (v / v). Stir on a magnetic stirrer until well mixed and set aside.

[0040] (4) Measure the required amount of colloidal gold solution 1 with a graduated cylinder, adjust the pH to 6.5-7.0, then add 0.2 mol / L potassium carbonate solution with a volume percentage concentration of 0.7%, and stir on a magnetic stirrer for 15 min to obtain colloidal gold solution 3.

[0041] Rabbit IgG antibody was diluted with double-distilled water and labeled at 10 μg / ml in colloidal gold solution 3. The volume ratio of double-distilled water to colloidal gold solution 3 was 5:100. The mixture was thoroughly mixed and stirred on a magnetic stirrer for 30 min. Then, 0.5‰ (v / v) of stabilizer PEG was added and stirred for another 30 min. The mixture was then centrifuged, and the precipitate was collected. The precipitate was reconstituted with colloidal gold reconstitution solution at a volume percentage of 5% and stirred on a magnetic stirrer until homogeneous. The mixture was then set aside for later use.

[0042] (4) Take the colloidal gold obtained in step (3) with a volume percentage concentration of 2% and redissolve it with colloidal gold redissolved solution at a volume percentage concentration of 5%, and record it as solution 1. Mix solution 1 evenly on a magnetic stirrer. Take the colloidal gold obtained in step (4) with a volume percentage concentration of 5% and redissolve it with colloidal gold redissolved solution at a volume percentage concentration of 20%, and record it as solution 2. Mix solution 2 evenly on a magnetic stirrer.

[0043] Mix thoroughly on a magnetic stirrer. Separately, add solutions 1 and 2 at a ratio of 2.5 μl / cm³. 2 The coating is sprayed onto the prepared colloidal gold polyester fiber strips and placed in a drying room to dry for ≥4 hours. The drying room temperature is controlled at 18-28℃, and the relative humidity is ≤40%, ensuring good airflow and preventing direct airflow onto the colloidal gold pad. The dried colloidal gold pad is then placed in an aluminum foil bag containing desiccant, sealed, and stored to obtain a solidified colloidal gold pad for later use. The two antibodies in the colloidal gold pad are labeled separately.

[0044] 3. Assembly and cutting: Take the semi-finished transparent substrate with the nitrocellulose membrane pasted in step 1, cut the solidified colloidal gold NC membrane into strips of 1.0cm×30cm and paste them onto the transparent substrate, keeping them overlapping the nitrocellulose membrane by about 1-2mm. Lay absorbent paper on the upper end of the transparent substrate membrane of the nitrocellulose membrane and overlap it with the membrane by about 1-2mm. Place the sample on the lower end of the solidified colloidal gold membrane and overlap it with it by about 1-2mm. Mark it and cut it for later use. Example 2: Preparation of the teretamine detection kit (1) According to the corresponding reaction apparatus, the telexamine test card prepared in Example 1 that has been assembled and ready for use is cut into strip test paper for later use.

[0045] (2) Place the prepared qualified test strip into the groove of the qualified test card with the handle paper on top, cover the card cover, and pinch it to obtain the test strip.

[0046] The structure of the prepared teretamine test kit is shown in the figure. Figures 1-2 The structure of the test kit is shown in [link to test kit]. Figures 3-4 .

[0047] Figure 1 The test card includes a plastic substrate 1, on which a sample pad 2 and an absorbent pad 3 are mounted. Both the sample pad 2 and the absorbent pad 3 are covered with a protective film 4. A nitrocellulose membrane 5 is located below and between the sample pad 2 and the absorbent pad 3. A colloidal gold adsorption pad 6 is located at the connecting end of the sample pad 2. One end of the colloidal gold adsorption pad 6 overlaps with one end of the nitrocellulose membrane 5. The nitrocellulose membrane 5 is sequentially coated with a test line T1 and a control line C1. The colloidal gold test pad 6 contains teletamine monoclonal antibody and rabbit IgG antibody. The test line is coated with teletamine conjugate and the control line is coated with goat anti-rabbit polyclonal antibody.

[0048] The present invention provides a telexamine test kit comprising a test kit top cover and a test kit bottom cover, wherein a groove is provided in the bottom cover and the test card is installed in the groove.

[0049] Application Example 1 1. Sample testing. Randomly sample from the same batch of samples to be tested. Since the number of samples required for each item is different, calculate the number of test strips needed for a complete test. The minimum sampling quantity shall not be less than three times the amount of test strips required.

[0050] After sampling, the samples to be inspected are placed in the yellow inspection area. Samples that can be inspected on the same day are inspected on the same day; otherwise, they must be inspected by the next day. The remaining paper strips that pass the inspection can be used as samples and temporarily placed in the qualified product area. Then, based on the production volume and sample retention requirements, a certain number of samples are randomly selected from the production line to be used as samples of the finished products.

[0051] 2. Required samples.

[0052] Telexamine sample solution: Prepare telexamine standards with negative urine to the corresponding concentrations: 500 ng / mL, 750 ng / mL, 1000 ng / mL, 1250 ng / mL, and 1500 ng / mL.

[0053] 3. Before testing, check the physical properties of the test kit or test card. (1) Inspect the appearance: Visually inspect the aluminum foil bag packaging to ensure it is intact and flat. Take out the test strip card and visually observe whether the colloidal gold, chromatography membrane, plastic substrate, sample pad, absorption pad and protective film of the test strip are complete. Also check whether the plastic shell fits firmly. (2) Check the width of the test strip: Take 3 test strips and measure the width of the film on the strip with a ruler.

[0054] After the test kit is prepared, calculate the liquid migration speed before testing: start timing with a stopwatch (accurate to 0.01s) from the moment the test strip is immersed in the sample solution until the liquid reaches the target depth. Figure 2 The timing stops at the boundary between zone E and zone F, and the time taken is recorded as (t). The length of (zone A + zone B + zone E) is measured with a vernier caliper (precision 0.02 mm) and recorded as (L). The transfer speed is calculated as L / t. Three test strips are measured repeatedly for each test strip, and the average value is taken. The result should meet the requirement that the liquid transfer speed is not less than 20 mm / min.

[0055] 4. The specific testing steps are as follows: Bring the telalamine test card (without opening the foil bag) and the sample to room temperature (20-30°C). Remove the telalamine test card from the foil bag and label it with the sample number. Place the test card flat on the table. Take out the plastic pipette from the bag, draw up a urine sample, and vertically add 2-3 drops of bubble-free urine sample into the sample well (S) of the test plate. Observe and record the results within 5 minutes; results after 10 minutes are invalid.

[0056] The criteria for judging test results are as follows: Negative samples (i.e., no teretamine was detected in the sample): Two purple-red bands appear at the test line and the control line (quality control line) in the observation window.

[0057] Positive samples (i.e., specimens containing teletamine): only one purple-red band appears at the quality control line in the observation window.

[0058] Invalid: The absence of a purple-red band on the quality control line indicates incorrect operation or a faulty kit.

[0059] 5. Perform the test according to the test steps in step 4 to determine the lowest detection limit: use telexamine sample solution for testing, and the lowest concentration at which a positive result appears is the lowest detection limit, which is 1000 ng / mL.

[0060] 6. Perform the testing according to the steps in step 4 to determine the repeatability: Randomly select 10 samples from the same batch of reagents (single package), and test them using 1000 ng / mL telexamine sample solution according to the steps in step 4. All results were positive, and the colorimetric intensity was uniform. This indicates that the telexamine test kit or test card of the present invention has good repeatability.

[0061] 7. Perform the tests according to the steps in step 4 to determine the test specificity: Test one sample each of morphine, methamphetamine, pseudoephedrine, benzoylecone, diazepam, phenobarbital, methadone, tramadol, and gatifloxacin at a concentration of 100 μg / mL; ranitidine and procaine at a concentration of 50 μg / mL; Δ9-tetrahydrocannabinol acid at a concentration of 10 μg / mL; and one negative urine sample. All test results were negative using the steps in step 4. This demonstrates that the telexamine test kit or test card of the present invention has good test specificity.

[0062] 8. Perform the testing according to the steps in step 4 to determine the inter-batch variation: Take three batches of test kit cards and test the repeatability of each batch. The test results of the three batches should be consistent. This demonstrates that the inter-batch variation of the telexamine test kit or test card of the present invention is small, and the product quality stability is high.

[0063] In summary, the telexamine test card and test kit provided by this invention have good repeatability and specificity, small batch-to-batch variation, and accurate and reliable test results.

[0064] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.

Claims

1. A telexamine test card, characterized in that, It includes a base plate, a sample loading pad, a colloidal gold pad, an NC membrane, and an absorbent pad; the base plate is provided with the sample loading pad, colloidal gold pad, NC membrane, and absorbent pad in sequence along the liquid chromatography direction; The colloidal gold pad is coated with a colloidal gold-labeled teletamine monoclonal antibody and a colloidal gold-labeled first antibody; the NC membrane is provided with a detection line and a control line in sequence along the liquid chromatography direction; the detection line is coated with a teletamine conjugate; the control line is coated with a second antibody; the second antibody can specifically bind to the first antibody.

2. The telexamine detection card according to claim 1, characterized in that, The first antibody includes rabbit IgG antibody; the second antibody includes goat anti-rabbit polyclonal antibody; and the teretamine conjugate includes a teretamine-bovine serum albumin conjugate.

3. The telexamine detection card according to claim 1, characterized in that, The concentration of the colloidal gold-labeled teretamine monoclonal antibody on the colloidal gold pad is 2-4 μg / mL. The concentration of the first antibody labeled with colloidal gold on the colloidal gold pad is 10~20 μg / mL; The coating concentration of the teretamine conjugate on the detection line is 0.3~0.6 mg / mL; The coating concentration of the second antibody on the quality control line is 1.0~2.0 mg / mL.

4. The telexamine detection card according to claim 1, characterized in that, The substrate of the colloidal gold pad includes polyester fiber strips.

5. The telexamine test card according to claim 1, characterized in that, On the NC membrane, the detection line is located on the side closer to the sample pad, and the quality control line is located on the side farther from the sample pad.

6. The method for preparing the telexamine test card according to any one of claims 1 to 5, characterized in that, include: 1) Spray the colloidal gold-labeled telactamine monoclonal antibody solution and the first antibody solution onto the pretreated colloidal gold pad to obtain a colloidal gold pad coated with telactamine monoclonal antibody and the first antibody. 2) Spray teletamine conjugate onto the detection line of the NC membrane; spray the second antibody onto the quality control line to obtain the coated NC membrane; after spraying, the NC membrane is blocked using a blocking treatment soaking solution prepared with phosphate buffer. The sample pad, the colloidal gold pad prepared in step 1), the NC membrane prepared in step 2), and the absorbent pad are sequentially pasted onto the base plate to obtain the telactamine detection card.

7. A telexamine colloidal gold detection kit, characterized in that, The kit comprises the teretamine test card according to any one of claims 1 to 5 or the teretamine test card prepared by the preparation method of claim 6.

8. A method for detecting teretamine, characterized in that, The method uses the telexamine test card as described in claims 1-5, the telexamine test card prepared by the preparation method described in claim 6, or the telexamine colloidal gold test kit as described in claim 7 to detect the sample to be tested.

9. The method according to claim 8, characterized in that, The sample to be tested includes urine.

10. The application of the teretamine test card according to any one of claims 1 to 5, the teretamine test card prepared by the preparation method according to claim 6, or the teretamine colloidal gold test kit according to claim 7 in the detection of teretamine.

Images